← Back to Clinical Trials
Recruiting NCT07072858

NCT07072858 Using Cardiac MRI to Predict Outcomes in Patients With STEMI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07072858
Status Recruiting
Phase
Sponsor Chinese PLA General Hospital
Condition Myocardial Infarction (MI)
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2014-01-01
Primary Completion 2025-12-30

Trial Parameters

Condition Myocardial Infarction (MI)
Sponsor Chinese PLA General Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2014-01-01
Completion 2025-12-30
Interventions
Cardiac Magnetic Resonance Imaging (CMR)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study integrates advanced artificial intelligence (AI) techniques to extract and analyze high-dimensional imaging features from multiple CMR sequences-including cine, strain mapping, and functional sequences-going beyond traditional measures such as infarct size or microvascular obstruction. The primary objective is to identify novel prognostic markers from routinely acquired CMR images that reflect myocardial structure, function, and mechanical deformation (strain), and to assess their association with long-term clinical outcomes. In addition to standard parameters, the study includes a detailed evaluation of left and right ventricular systolic and diastolic volumes, ejection fractions, and biventricular strain components (including longitudinal, circumferential, and radial strain), as well as left and right atrial volumes, emptying fractions, and reservoir/conduit/booster strain indices. Approximately 1000 STEMI patients will undergo CMR scanning within one week after PCI. The imaging data will be subjected to AI-based feature extraction and dimensionality reduction algorithms to uncover latent patterns associated with adverse outcomes. Patients will be followed for up to three years for the occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, recurrent myocardial infarction, and heart failure hospitalization. The central hypothesis is that comprehensive CMR functional and strain-derived parameters, when analyzed using AI-driven models, offer independent and incremental prognostic value beyond conventional clinical risk factors. This study seeks to establish a data-driven, multimodal imaging framework for personalized risk stratification in STEMI patients, potentially enabling more precise post-infarction management strategies. No investigational treatment is involved. All imaging and clinical data are collected as part of routine care and analyzed retrospectively for outcome prediction.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 80 years Diagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels Underwent primary percutaneous coronary intervention (PCI) Able to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI Provided written informed consent Exclusion Criteria: * Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers) History of revascularization therapy (PCI or CABG) within the previous 6 months Severe valvular heart disease or known cardiomyopathy Presence of bundle branch block or fascicular block that interferes with image interpretation Known allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences) Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² (if contrast use is anticipated) Pregnant or breastfeeding women

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology